No Data
Zhixiang Jintai (688443.SH): a total of 0.1776% of the company's shares have been repurchased.
On March 3, Gelonghui reported that Zhixiang Jintai (688443.SH) announced that as of February 28, 2025, the company has cumulatively repurchased 651,207 shares of the company through the centralized bidding trading method via the Shanghai Stock Exchange trading system, accounting for 0.1776% of the company's total share capital of 366,680,000 shares, with a highest transaction price of 28.257 yuan per share, a lowest transaction price of 23.23 yuan per share, and a total payment of 16,797,393.41 yuan (excluding commissions, transfer fees, and other transaction expenses).
Zhixiang Jintai: 2024 Annual Results Report
2024 Annual Results Report
Zhixiang Jintai (688443.SH): Net loss of 0.8 billion yuan in 2024.
On February 27, Glonghui announced that ZhiXiang JinTai (688443.SH) reported its performance forecast for the fiscal year 2024, with a total revenue of 30.09 million yuan, a year-on-year increase of 2384.10%, and a net income attributable to parent company owners of -0.8 billion yuan. During the reporting period, the company adhered to source innovation and efficiently advanced the progress of various research projects. With multiple products entering the clinical research stage and core products entering key clinical trial stages, the company maintained a high level of R&D investment in ongoing projects. During the reporting period, the company experienced significant revenue growth, mainly due to the approval and sales of its monoclonal antibody injection, Salichi (Jinlixi).
Chongqing Genrix Biopharmaceutical Starts Phase III Trial for GR1802 Injection in Urticaria
Painful Week for Private Equity Firms Invested in Chongqing Genrix Biopharmaceutical Co., Ltd. (SHSE:688443) After 4.0% Drop, Institutions Also Suffered Losses
